Organon to Showcase VTAMA Efficacy Data Across Age Groups at Pediatric Dermatology Meeting
Event summary
- Organon will present new Phase 3 data on VTAMA cream for atopic dermatitis at the 2026 SPD Annual Meeting on July 23.
- The analysis pools results from ADORING 1 and ADORING 2 trials, evaluating efficacy across pediatric and adult patients.
- VTAMA is the only aryl hydrocarbon receptor agonist approved for both plaque psoriasis and atopic dermatitis in adults and children aged 2+.
- AAD issued strong recommendations for VTAMA's use in treating atopic dermatitis in specified age groups.
The big picture
Organon's presentation underscores its strategic focus on dermatology, particularly in addressing unmet needs across age groups. The pooled analysis could strengthen VTAMA's position against competitors like Pfizer's Eucrisa and LEO Pharma's Triderm, especially as pediatric-specific treatments gain regulatory and clinical traction. With atopic dermatitis affecting over 10% of children globally, this data may influence prescribing patterns in a market projected to exceed $25 billion by 2030.
What we're watching
- Market Differentiation
- Whether VTAMA's dual indication status will drive competitive advantage in the atopic dermatitis market.
- Regulatory Tailwinds
- The pace at which AAD recommendations translate into broader clinical adoption and payer coverage.
- Pediatric Focus
- How Organon leverages this data to expand VTAMA's market share in the underserved pediatric dermatology segment.
Related topics